Recently, Suzhou Minghua Sugar Alcohol Co., Ltd. (hereinafter referred to as "Minghua Sugar Alcohol")—a company with nearly forty years of deep-rooted expertise in the sugar alcohol industry—officially announced that its independently upgraded production facility for high-purity, pharmaceutical-grade liquid sorbitol has successfully achieved stable mass production. The facility's key performance indicators fully comply with the dual standards of both the *United States Pharmacopeia* (USP) and the *European Pharmacopoeia* (EP). This achievement further breaks the long-standing domestic reliance on imports for high-end pharmaceutical excipients, offering a new option for domestic pharmaceutical manufacturers seeking to optimize costs and ensure supply security.
From Food Sweeteners to Pharmaceutical Excipients: The High-End Upgrade of Liquid Sorbitol
Liquid sorbitol (D-Sorbitol Solution 70%) is a polyol product derived from the catalytic hydrogenation of glucose. Due to its characteristics—including low sweetness, non-cariogenicity, high stability, and excellent compatibility with active pharmaceutical ingredients—it is widely utilized in pediatric oral solutions, syrups, chewable tablets, lozenges, oral care products, and even as an excipient in injectable formulations. However, for pharmaceutical-grade applications, the requirements regarding heavy metals, reducing sugars, conductivity, and microbial load are significantly more stringent than those for food-grade products. Consequently, for a considerable period, more than 80% of the domestic market share for high-end pharmaceutical-grade liquid sorbitol has been dominated by a few international industry giants.
Since its inception in 1987—succeeding its predecessor, the Suzhou Minghua Chemical Factory—Minghua Sugar Alcohol has focused intently on research into sorbitol hydrogenation processes, accumulating eighteen years of continuous technological expertise in this field. The core of this latest mass-production breakthrough lies in the company's decision to build upon traditional stirred-tank batch hydrogenation methods by introducing a new generation of tubular continuous hydrogenation technology and a highly selective catalyst system. By integrating these innovations with an independently designed purification platform—which couples multi-stage ion exchange with reverse osmosis—the company has successfully reduced heavy metal content in the product to below 10 ppm and controlled reducing sugar levels to under 0.15%, while consistently maintaining conductivity levels that surpass the specifications listed in both the USP and EP. Compliant with Four Major Pharmacopoeias (USP/EP/JP/CP): Comprehensive Quality Assurance
According to the head of the Minghua Sugar Alcohol Technical Center, the company's new generation of pharmaceutical-grade liquid sorbitol has simultaneously passed the testing and verification standards of four major pharmacopoeias: the *United States Pharmacopeia* (USP), the *European Pharmacopoeia* (EP), the *Japanese Pharmacopoeia* (JP), and the *Pharmacopoeia of the People's Republic of China* (ChP). Furthermore, the product has obtained HALAL, Kosher, and Food Chemicals Codex (FCC) certifications, thereby meeting the compliance requirements of major global markets.
In terms of production management, the company leverages fully automated production lines adhering to international GMP standards, an integrated online QA/QC monitoring system, and its own fleet of ISO-tank transport vehicles. This infrastructure ensures "monitorable, manageable, and traceable" end-to-end quality assurance—spanning everything from raw materials, processing, and storage/transportation to final delivery. Customers can customize liquid sorbitol products to meet their specific formulation needs—selecting from various concentrations (e.g., 60% or 70%) and purity grades—while benefiting from an expedited two-hour delivery service within the Yangtze River Delta region.
Driving Domestic Substitution: Making High-Quality Excipients Affordable and Accessible for Chinese Pharmaceutical Manufacturers
In recent years, with the normalization of centralized procurement policies and the implementation of the "associated review" policy for APIs and excipients, the localization, regulatory compliance, and large-scale production of pharmaceutical excipients have become essential requirements for the industry. The successful launch of Minghua Sugar Alcohol’s mass-produced pharmaceutical-grade liquid sorbitol not only significantly reduces the import lead times and costs for domestic pharmaceutical manufacturers but also—through a consistent and stable supply chain—offers a tangible, practical domestic alternative for a wide range of pharmaceutical formulations, including oral solutions, chewable tablets, syrups, mouthwashes, and pediatric antipyretics.
Looking ahead, Minghua Sugar Alcohol will focus on a dual-pillar strategy centered on "Sugar Alcohols + Pharmaceutical Excipients." The company plans to accelerate the development and market rollout of a comprehensive portfolio of pharmaceutical excipients—including pharmaceutical-grade maltitol, xylitol, mannitol, and polyethylene glycol (PEG). Furthermore, leveraging its state-of-the-art in-house R&D laboratories, the company intends to establish joint formulation laboratories in collaboration with downstream pharmaceutical manufacturers and API producers, thereby providing deep-level support from the raw material end to drive the high-quality development of China's pharmaceutical industry.
From Food Sweeteners to Pharmaceutical Excipients: The High-End Upgrade of Liquid Sorbitol
Liquid sorbitol (D-Sorbitol Solution 70%) is a polyol product derived from the catalytic hydrogenation of glucose. Due to its characteristics—including low sweetness, non-cariogenicity, high stability, and excellent compatibility with active pharmaceutical ingredients—it is widely utilized in pediatric oral solutions, syrups, chewable tablets, lozenges, oral care products, and even as an excipient in injectable formulations. However, for pharmaceutical-grade applications, the requirements regarding heavy metals, reducing sugars, conductivity, and microbial load are significantly more stringent than those for food-grade products. Consequently, for a considerable period, more than 80% of the domestic market share for high-end pharmaceutical-grade liquid sorbitol has been dominated by a few international industry giants.
Since its inception in 1987—succeeding its predecessor, the Suzhou Minghua Chemical Factory—Minghua Sugar Alcohol has focused intently on research into sorbitol hydrogenation processes, accumulating eighteen years of continuous technological expertise in this field. The core of this latest mass-production breakthrough lies in the company's decision to build upon traditional stirred-tank batch hydrogenation methods by introducing a new generation of tubular continuous hydrogenation technology and a highly selective catalyst system. By integrating these innovations with an independently designed purification platform—which couples multi-stage ion exchange with reverse osmosis—the company has successfully reduced heavy metal content in the product to below 10 ppm and controlled reducing sugar levels to under 0.15%, while consistently maintaining conductivity levels that surpass the specifications listed in both the USP and EP. Compliant with Four Major Pharmacopoeias (USP/EP/JP/CP): Comprehensive Quality Assurance
According to the head of the Minghua Sugar Alcohol Technical Center, the company's new generation of pharmaceutical-grade liquid sorbitol has simultaneously passed the testing and verification standards of four major pharmacopoeias: the *United States Pharmacopeia* (USP), the *European Pharmacopoeia* (EP), the *Japanese Pharmacopoeia* (JP), and the *Pharmacopoeia of the People's Republic of China* (ChP). Furthermore, the product has obtained HALAL, Kosher, and Food Chemicals Codex (FCC) certifications, thereby meeting the compliance requirements of major global markets.
In terms of production management, the company leverages fully automated production lines adhering to international GMP standards, an integrated online QA/QC monitoring system, and its own fleet of ISO-tank transport vehicles. This infrastructure ensures "monitorable, manageable, and traceable" end-to-end quality assurance—spanning everything from raw materials, processing, and storage/transportation to final delivery. Customers can customize liquid sorbitol products to meet their specific formulation needs—selecting from various concentrations (e.g., 60% or 70%) and purity grades—while benefiting from an expedited two-hour delivery service within the Yangtze River Delta region.
Driving Domestic Substitution: Making High-Quality Excipients Affordable and Accessible for Chinese Pharmaceutical Manufacturers
In recent years, with the normalization of centralized procurement policies and the implementation of the "associated review" policy for APIs and excipients, the localization, regulatory compliance, and large-scale production of pharmaceutical excipients have become essential requirements for the industry. The successful launch of Minghua Sugar Alcohol’s mass-produced pharmaceutical-grade liquid sorbitol not only significantly reduces the import lead times and costs for domestic pharmaceutical manufacturers but also—through a consistent and stable supply chain—offers a tangible, practical domestic alternative for a wide range of pharmaceutical formulations, including oral solutions, chewable tablets, syrups, mouthwashes, and pediatric antipyretics.
Looking ahead, Minghua Sugar Alcohol will focus on a dual-pillar strategy centered on "Sugar Alcohols + Pharmaceutical Excipients." The company plans to accelerate the development and market rollout of a comprehensive portfolio of pharmaceutical excipients—including pharmaceutical-grade maltitol, xylitol, mannitol, and polyethylene glycol (PEG). Furthermore, leveraging its state-of-the-art in-house R&D laboratories, the company intends to establish joint formulation laboratories in collaboration with downstream pharmaceutical manufacturers and API producers, thereby providing deep-level support from the raw material end to drive the high-quality development of China's pharmaceutical industry.
